Advertisement

Search Results

Advertisement



Your search for this matches 25381 pages

Showing 25151 - 25200


lung cancer

Intercalated Chemotherapy plus Erlotinib Improves Survival in Asian Patients with Advanced NSCLC and Known or Unknown EGFR Mutation Status

In a phase III trial (FASTACT-2) conducted in 28 centers in seven Asian countries, Yi-Long Wu, MD, of the Guangdong Academy of Medical Sciences and colleagues found that the intercalated combination of erlotinib (Tarceva) and chemotherapy improved progression-free survival vs chemotherapy alone as...

issues in oncology

WHO Tobacco Control Policies Estimated to Prevent 7.4 Million Premature Deaths by 2050

Tobacco control measures put in place in 41 countries between 2007 and 2010 are predicted to prevent an estimated 7.4 million premature deaths by 2050, according to a study published in the July issue of the Bulletin of the World Health Organization. The study is one of the first to ...

issues in oncology
breast cancer

Biomarker Predicts Risk of Breast Cancer Recurrence after Tamoxifen Treatment

A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment. In a report published online in the Journal...

breast cancer
supportive care
integrative oncology

Acupuncture May Reduce Arm Lymphedema in Patients with Breast Cancer

Arm lymphedema affects approximately 30% of breast cancer survivors, with rates increasing with longer follow-up and cases presenting well beyond the active treatment period. Lymphedema is observed even with use of less-invasive surgical techniques for staging, and risk is further increased by such ...

solid tumors
kidney cancer

Progression of Renal Cell Carcinoma Linked to Shifts in Tumor Metabolism

Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma. Their findings demonstrate that normal...

issues in oncology
issues in oncology

Scientists Develop Mathematical Model to Predict Cancer Cells’ Resistance to Therapy

New research using mathematical models of different types of cancer—including melanoma, pancreatic, and colorectal—to determine the evolutionary dynamics of lesions in response to treatment is revealing why and how cancer cells resist targeted therapies. The study by Ivana Bozic, PhD,...

skin cancer

Surgeons Report Melanoma Recurs after 10 Years in More than 6% of Patients

Recurrence of melanoma skin cancer 10 or more years after initial treatment is more common than previously thought, occurring in more than 1 in 20 patients. However, according to a new study, these patients tend to live longer after their cancer returns than patients whose melanoma recurs in the...

lung cancer

Crizotinib Improves Progression-free Survival vs Pemetrexed or Docetaxel in Advanced ALK-positive NSCLC

In a phase III trial reported by Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, and colleagues in The New England Journal of Medicine, crizotinib (Xalkori) improved progression-free survival compared with standard chemotherapy in previously treated patients with advanced...

prostate cancer

Novel Research Method May Lead to Tailored Treatments for Late-stage Prostate Cancer

A study using a novel “co-clinical” approach that integrates data from hundreds of genetically engineered mouse models with clinical data from tissue samples of hundreds of patients with castration-resistant prostate cancer, has identified several molecular pathways underlying...

prostate cancer

Active Surveillance May Miss Aggressive Prostate Cancers in African American Men

A study of more than 1,800 men aged 52 to 62 suggests that African Americans diagnosed with very low-risk prostate cancers are much more likely than white men to actually have aggressive disease that goes unrecognized with current diagnostic approaches. Although prior studies have found it safe to...

skin cancer

Among White Adolescents and Young Adults with Melanoma, Males Have Higher Mortality Than Females

Melanoma is the third most common cancer among adolescents and young adults, but few studies have explored the survival differences by sex in this population. A new study published in JAMA Dermatology sought to determine whether long-term survival varied between white male and female...

supportive care
issues in oncology

Majority of Patients with Incurable Lung Cancer Have Inaccurate Expectations about Goals of Radiation Therapy

Aileen B. Chen, MD, MPP, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and colleagues in the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium recently assessed patient expectations regarding goals of radiation therapy (RT) for incurable lung cancer. They ...

lymphoma

Lugano 2013: Vitamin D Deficiency Associated with Worse Outcome in Elderly Patients with Aggressive B-cell Lymphoma Receiving R-CHOP or CHOP

Vitamin D deficiency recently was shown to be associated with worse outcome in patients with non-Hodgkin lymphoma. To determine whether such an association exists in patients with aggressive B-cell lymphoma, Jörg T. Bittenbring, of Saarland University Medical School, Germany, and colleagues in ...

lymphoma

Lugano 2013: Chlorambucil plus Rituximab Produces Better Event-free and Progression-free Survival in Extranodal Marginal Zone B-cell Lymphoma

The International Extranodal Lymphoma Study Group (IELSG)-19 trial is the largest randomized trial in extranodal marginal zone B-cell lymphoma conducted to date. As reported by Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland, and colleagues, preliminary final results of the...

breast cancer

Study Shows Isoflavone Exposure Has Little Effect on Breast Cancer Risk or Recurrence

According to a review of studies examining the impact of isoflavones in soyfoods on breast cancer risk, clinical evidence indicates that exposure to isoflavones, which are classified as both phytoestrogens and selective estrogen receptor modulators, has little effect on the markers of breast cancer ...

colorectal cancer

BRAF Mutation Status May Have Effect on Benefit of Aspirin Use for Patients with Colorectal Cancer

In two large studies, the association between aspirin use and risk of colorectal cancer was affected by BRAF mutation status, with regular aspirin use associated with a lower risk of BRAF wild-type colorectal cancer but not with risk of BRAF-mutated cancer. The findings, published today in JAMA,...

prostate cancer

Use of Advanced Treatment Technologies Increases among Men at Low Risk of Dying from Prostate Cancer

Use of advanced treatment technologies for prostate cancer, such as intensity-modulated radiotherapy (IMRT) and robotic prostatectomy, has increased among men with low-risk disease, high risk of noncancer mortality, or both, a population of patients who are unlikely to benefit from these...

issues in oncology

New Study Finds AICR Recommendations Cut Breast Cancer Risk

Postmenopausal women who follow at least five Recommendations for Cancer Prevention from the American Institute for Cancer Research (AICR) cut their risk of developing breast cancer by more than half, compared to those who meet none, suggests a new study that adds to previous research showing...

issues in oncology

Researchers Identify and Map Signaling Pathway from EGFR to MCM7 Protein

Researchers have discovered and mapped the signaling network between two previously unconnected proteins, exposing a link that, if broken, could cut off cancer cell growth at its starting point. A team led by scientists at The University of Texas MD Anderson Cancer Center reported the tie between...

issues in oncology
head and neck cancer

Investigators Identify Promising Biomarker for Predicting HPV-related Oropharyngeal Cancer

Researchers have found that antibodies against the human papillomavirus (HPV) may help identify individuals who are at greatly increased risk of HPV-related cancer of the oropharynx, In their study, at least one in three individuals with oropharyngeal cancer had antibodies to HPV, compared to...

multiple myeloma

Deep Sequencing Accurately Predicts Prolonged Survival in Multiple Myeloma Patients

A study by the Spanish Myeloma Group comparing the prognostic value of traditional response criteria and minimal residual disease measurement in patients with multiple myeloma found that a sequencing-based method called LymphoSIGHT and multiparameter flow cytometry analysis both accurately...

gynecologic cancers
gynecologic cancers
issues in oncology

Study Shows HPV Vaccine Reduced Rate of Infection in Teenage Girls by 56%

A new government study investigating the prevalence of human papillomavirus (HPV) infections in females aged 14 to 59 before and after the introduction in 2006 of the HPV vaccine found that the rate of the HPV infection dropped by 56%, decreasing from 11.5% in 2006 to 5.1% in 2010 among female...

cns cancers

Virus Combination Effective Against Temozolomide-resistant Glioblastoma Multiforme

A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to new research published in Neuro-Oncology. Study lead author Peter A. Forsyth, MD, Chair of the Neuro-oncology Program at Moffitt ...

lung cancer

First-line Carboplatin plus Pemetrexed Improves Survival vs Pemetrexed Alone in Patients with Advanced NSCLC and Poor Performance Status

A significant proportion of patients with advanced non–small cell lung cancer (NSCLC) have poor performance status, and optimal clinical management of these patients has not been established. In an attempt to help define optimal chemotherapy in such patients, Mauro Zukin, MD, of Instituto...

skin cancer

Mortality Appears to be Higher for Patients with Thicker Single Primary Melanomas than for Thicker Multiple Primary Melanomas

Although overall mortality rates due to single primary melanomas and multiple primary melanomas appear to be similar, relative mortality for thicker single primary melanomas appears to be greater than that for thicker multiple primary melanomas, according to a study by Anne Kricker, PhD, of the...

prostate cancer

Observation Is Safe, Cost-saving Option for Patients with Low-risk Prostate Cancer

Many men with low-risk, localized prostate cancers can safely choose active surveillance or watchful waiting instead of undergoing immediate treatment and have better quality of life while reducing health-care costs, according to a study by researchers at Dana-Farber Cancer Institute and...

lung cancer

Novel Selective ALK Inhibitor Demonstrates Good Activity in Advanced NSCLC

Crizotinib (Xalkori), a multitargeted receptor tyrosine kinase inhibitor, is the only agent currently available for treating ALK-rearranged non–small cell lung cancer (NSCLC). CH5424802 is a novel selective oral ALK inhibitor with activity in tumor cell lines harboring ALK alterations,...

issues in oncology
issues in oncology

Global Alliance Is Formed to Share Genomic Data

This month, an international group of over 70 research and health-care organizations, academic centers, and medical societies, including ASCO, signed a letter of intent to form a global alliance to make medicine more effective by consolidating the world’s databases of genomic information. The ...

breast cancer

PHARE Trial Fails to Establish Noninferiority of 6 vs 12 Months of Adjuvant Trastuzumab in Early HER2-positive Breast Cancer

The phase III open-label PHARE trial, conducted in 156 centers in France, examined whether 6 months of adjuvant trastuzumab (Herceptin) was noninferior to 12 months of treatment in women with early HER2-positive breast cancer. As reported by Xavier Pivot, MD, of University Hospital Jean-Minjoz,...

colorectal cancer

Impact of Age on Efficacy of Newer Adjuvant Therapies in Patients with Stage II/III Colon Cancer

Available data suggest that patients with stage II/III colon cancer receive similar benefit from intravenous fluorouracil (5-FU) adjuvant therapy regardless of age. Combination regimens and oral fluoropyrimidine therapy are now standard treatments in this setting. Nadine J. McCleary, MD, MPH, and...

breast cancer

Acetyl-L-carnitine Ineffective for Taxane-related Peripheral Neuropathy

Various studies have suggested that acetyl-L-carnitine, a natural compound involved in neuronal protection, may be effective in preventing and treating sensory neuropathy. Dawn L. Hershman, MD, MS, of Columbia University Medical Center, and colleagues recently assessed whether daily...

colorectal cancer

ASCO 2013: Genomic Heterogeneity Can Lead to the Selection of ‘Incorrect’ Targeted Inhibitors

Genomic heterogeneity within tumors and among lesions varies widely, and “discordance among lesions could lead to the selection of the ‘incorrect’ targeted inhibitor,” according to David B. Solit, MD, of Memorial Sloan-Kettering Cancer Center, who spoke at the ASCO/American...

NCI Will No Longer Accept R01 and P01 Applications for Phase III Clinical Trials of Medical Interventions and Cancer Imaging Modalities

The National Cancer Institute (NCI) has announced that it will no longer accept investigator-initiated R01 and P01 applications that propose phase III clinical trials for cancer-related medical interventions or cancer imaging modalities. The policy change takes effect starting with the due date of...

FDA Approves New Silicone Gel-filled Breast Implant

The FDA recently approved the MemoryShape Breast Implant for breast augmentation in women at least 22 years old and for breast reconstruction in women of any age. The MemoryShape Breast Implants are manufactured by Mentor Worldwide LLC. The FDA’s approval is based on 6 years of data from 955 ...

issues in oncology
breast cancer

Abnormalities in New Molecular Pathway May Increase Breast Cancer Risk

A new molecular pathway involving the gene ZNF365 has been identified, and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. “Genomic...

breast cancer

Osteoporosis Drug Stops Growth of Breast Cancer Cells in Tamoxifen-resistant Tumors

A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a study presented at the Endocrine Society’s 95th Annual Meeting in San Francisco. The findings ...

cns cancers

Metabolic Molecule Drives Growth of High-grade Glioma

A study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) has identified an abnormal metabolic pathway that drives cancer cell growth in a particular glioblastoma...

breast cancer

Developmental Protein Plays Role in Spread of Cancer

A protein used by embryo cells during early development, and recently found in many different types of cancer, may serve as a switch regulating metastasis, according to researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center. The findings were ...

breast cancer

Younger Age Does Not Significantly Impact Recurrence or Benefit from Trastuzumab in Early-stage HER2-positive Breast Cancer

Available data suggest that younger age is an independent risk factor for disease recurrence and death in women with breast cancer. However, there has not been adequate study of the interaction of age with human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. In an analysis ...

breast cancer
issues in oncology

Newly Identified Markers May Predict Who Will Respond to Breast Cancer Prevention Therapy

Single nucleotide polymorphisms (SNPs) in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. ...

lung cancer
issues in oncology

ASCO 2013: First Prospective Trial Shows Molecular Profiling Timely for Tailoring Therapy

A clinical trial has shown that patients and their physicians are eager to jump into the next generation of cancer care: analysis of an individual’s tumor to find and target genetic mutations that drive the cancer. Results of the study, CUSTOM, were presented at the 2013 ASCO Annual Meeting...

colorectal cancer

ASCO 2013: Lung Cancer Mutations ALK and ROS1 Also Drive Colorectal Cancer

A study from the University of Colorado Cancer Center shows that the ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. Results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of...

breast cancer

Research Team Identifies Genetic Risk for Cancer in Breast Cells

An Indiana University cancer researcher and his Canadian collaborator have discovered how normal breast precursor cells may be genetically vulnerable to developing into cancer. David Gilley, PhD, Associate Professor of Medical and Molecular Genetics at the IU School of Medicine and a researcher at ...

issues in oncology

ASCO 2013: Top Five Things Oncologists Need to Know about Cancer in Older Adults

A workforce shortage of geriatricians and other health professionals trained and certified in caring for older patients with cancer is colliding with the aging of the population and the increasing number of older Americans with cancer. After describing factors contributing to these dual challenges, ...

health-care policy
legislation

CMS Says It Lacks Authority to Roll Back Sequestration Cuts to Medicare Payments for Part B Cancer Drugs

According to a June 3 letter from the Centers for Medicare and Medicaid Services (CMS), there will be no reprieve in the 2% ($11.08 billion) reduction to Medicare providers and hospitals mandated by the federal budget sequestration. The letter by CMS Acting Administrator Marilyn Tavenner was in...

lymphoma

Radioimmunotherapy/Chemotherapy Combination Could Extend Survival in Some Patients with Advanced Lymphoma

A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy showed encouraging overall survival rates in some patients preparing for autologous bone marrow transplant, reported researchers at the 2013 Annual Meeting of the Society of...

lymphoma

Study Paves Way for Rational Drug Targeting of B-cell Lymphomas

A new study from Dana-Farber Cancer Institute may help clinicians and drug researchers choose the most promising genetic targets to attack in a common type of non-Hodgkin lymphoma. The report, published in the June 10 issue of Cancer Cellprovides a new, “big picture” view of an...

breast cancer
issues in oncology

Sequential PET/MRI Predicts Chemotherapy’s Ability to Improve Survival in Patients with Advanced Breast Cancer

For patients with advanced breast cancer, positron-emission tomography (PET) and magnetic resonance imaging (MRI) can improve quality of life and survival by providing physicians with information on the effectiveness of chemotherapy prior to surgery, according to researchers presenting at the 2013...

Reducing Unnecessary and High-dose Pediatric CT Scans Could Cut Future Cancers by More than Half

A study examining trends in x-ray computed tomography (CT) use in children in the United States has found that reducing unnecessary scans and lowering the doses for the highest-dose scans could lower the overall lifetime risk of future imaging-related cancers by 62%. The research was published...

health-care policy

National Institutes of Health Issues Projected Impact of Sequestration on Programs

Earlier this month, the National Institutes of Health (NIH) released its updated projections of reductions in programs due to the deficit-budget mechanism known as sequestration, which took effect on March 1, 2013. The sequestration law requires NIH to cut 5%, or $1.55 billion, of its fiscal year...

Advertisement

Advertisement




Advertisement